ExpreS2ion Biotech Price To Book vs. Z Score
| EXPRS2 Stock | SEK 20.85 1.87 9.85% |
For ExpreS2ion Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ExpreS2ion Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ExpreS2ion Biotech Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ExpreS2ion Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ExpreS2ion Biotech Holding over time as well as its relative position and ranking within its peers.
ExpreS2ion |
ExpreS2ion Biotech Z Score vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ExpreS2ion Biotech's current stock value. Our valuation model uses many indicators to compare ExpreS2ion Biotech value to that of its competitors to determine the firm's financial worth. ExpreS2ion Biotech Holding is one of the top stocks in price to book category among its peers. It also is one of the top stocks in z score category among its peers totaling about 24.57 of Z Score per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value ExpreS2ion Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ExpreS2ion Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.ExpreS2ion Z Score vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ExpreS2ion Biotech |
| = | 3.42 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
ExpreS2ion Biotech |
| = | 84.0 |
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
ExpreS2ion Z Score Comparison
ExpreS2ion Biotech is currently under evaluation in z score category among its peers.
ExpreS2ion Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ExpreS2ion Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ExpreS2ion Biotech will eventually generate negative long term returns. The profitability progress is the general direction of ExpreS2ion Biotech's change in net profit over the period of time. It can combine multiple indicators of ExpreS2ion Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ExpreS2ion Biotech Holding AB , through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark. ExpreS2ion Biotech operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 15 people.
ExpreS2ion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ExpreS2ion Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ExpreS2ion Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ExpreS2ion Biotech's important profitability drivers and their relationship over time.
Use ExpreS2ion Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ExpreS2ion Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ExpreS2ion Biotech will appreciate offsetting losses from the drop in the long position's value.ExpreS2ion Biotech Pair Trading
ExpreS2ion Biotech Holding Pair Trading Analysis
The ability to find closely correlated positions to ExpreS2ion Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ExpreS2ion Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ExpreS2ion Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ExpreS2ion Biotech Holding to buy it.
The correlation of ExpreS2ion Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ExpreS2ion Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ExpreS2ion Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ExpreS2ion Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ExpreS2ion Biotech position
In addition to having ExpreS2ion Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Non-Metallic and Industrial Metal Mining Thematic Idea Now
Non-Metallic and Industrial Metal Mining
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Non-Metallic and Industrial Metal Mining theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Non-Metallic and Industrial Metal Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in ExpreS2ion Stock
To fully project ExpreS2ion Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ExpreS2ion Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ExpreS2ion Biotech's income statement, its balance sheet, and the statement of cash flows.